InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.770 0.18 (6.95%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3,592 Cell Patents for Cardiac Disease- New Clinical Opportunities 6 Feb 2007 8:38AM $2.300 $2.770 risen by 20.43%
$3,592 Commitments Test Entity - Second Quarter Report 31 Jan 2007 4:40PM $2.200 $2.770 risen by 25.91%
$3,592 FDA Clearance for Phase 2 Stem Cell Trial 18 Dec 2006 9:12AM $1.780 $2.770 risen by 55.62%
$3,592 Files FDA Submission 21 Nov 2006 9:41AM $1.660 $2.770 risen by 66.87%
$3,592 Stem Cell Heart Attack Trial-Positive Preclinical Results 14 Nov 2006 9:37AM $1.655 $2.770 risen by 67.37%
$3,592 Commitments Test Entity - First Quarter Report 30 Oct 2006 10:48AM $1.435 $2.770 risen by 93.03%
$3,592 Major stem cell patent granted in US 18 Oct 2006 9:03AM $1.480 $2.770 risen by 87.16%
$3,592 Investment in Angioblast for Phase II Cardiovascular Trial 21 Sep 2006 11:42AM $1.180 $2.770 risen by 134.75%
$3,592 Heart Function Improves in Stem Cell Trials 19 Sep 2006 10:03AM $1.235 $2.770 risen by 124.29%
$3,592 Preliminary Final Report/Full Year Accounts 13 Sep 2006 6:02PM $1.180 $2.770 risen by 134.75%
$3,592 Stem Cell Bone Repair Trials Produce Outstanding Results 22 Aug 2006 1:32PM $1.340 $2.770 risen by 106.72%
$3,592 Commitments Test Entity - Fourth Quarter Report 27 Jul 2006 10:59AM $1.330 $2.770 risen by 108.27%
$3,592 Locks in next stage of Growth 20 Jul 2006 9:54AM $1.320 $2.770 risen by 109.85%
$3,592 Trading Halt 18 Jul 2006 10:56AM n/a $2.770 n/a
$3,592 Targets major cartilage markets 4 Jul 2006 10:22AM $1.410 $2.770 risen by 96.45%
$3,592 Achieves major milestones/Positive results/Commercialisation 7 Jun 2006 11:04AM $1.630 $2.770 risen by 69.94%
$3,592 Positive results in preclinical trials for heart failure 22 May 2006 10:41AM $1.400 $2.770 risen by 97.86%
$3,592 Significant Progress in Clinical Trials 16 May 2006 9:32AM $1.380 $2.770 risen by 100.72%
$3,592 Commitments Test Entity - Third Quarter Report 28 Apr 2006 4:16PM $1.490 $2.770 risen by 85.91%
$3,592 Positive results confirm spinal fusion as major market 27 Apr 2006 9:42AM $1.600 $2.770 risen by 73.13%
$3,592 First Adult Stem Cells for Long Bone Fracture Patient 3 Apr 2006 11:45AM $1.800 $2.770 risen by 53.89%
$3,592 Next generation drug eluting stent technology 22 Mar 2006 9:48AM $1.690 $2.770 risen by 63.91%
$3,592 Half Yearly Report & Half Year Accounts 13 Mar 2006 12:19PM $1.850 $2.770 risen by 49.73%
$3,592 Pre-Clinical Studies validate universal donor business model 13 Feb 2006 9:16AM $1.645 $2.770 risen by 68.39%
$3,592 Commitments Test Entity - Second Quarter Report 31 Jan 2006 5:02PM $1.290 $2.770 risen by 114.73%

1126 - 1150 of 1167 results

Page 46 of 47

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.